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Presented in this master’s thesis are several studies carried out to determine the 
viability of several allergoid candidates utilizing the major peanut allergen Ara h 2. The 
Ara h 2 allergen protein appears naturally as a doublet when observed by gel 
electrophoresis, SDS-PAGE.  Optimization of allergen purification methods successfully 
led to Ara h 2 purity, and the ability to standardize procedures to yield consistently pure 
samples. The purified allergen was chemically crosslinked with diketone derivatives 
selected for their abilities to react with specific amino acids accessible on the Ara h 2 
protein. Chemically modified allergen samples were also evaluated using SDS-PAGE; 
successful protein modifications were identified by doublet band smearing or even 
oligomer formations such as dimers and trimers. Immunoassays were then applied to 
determine if epitope surface region is disrupted to indicate the diminished immune 
responsiveness to the modified allergen. Ara h 2 IgE specific antibodies, through western 
blot analysis, were used to determine antibody affinity between chemically modified and 
unmodified allergen proteins and to characterize any differences between the allergen 
samples. Results indicate that Ara h 2 may be chemically crosslinked using functional 
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Significance of Peanut Allergies 
Food allergies are a major health concern for patients and for the healthcare 
providers who are tasked with the responsibility to treat them, because of the rapid onset 
and limited treatment options available in case of emergency. Currently, 8 foods are 
associated with food related allergies because of the immune reaction they have the 
potential to elicit in allergic individuals1. Food allergies are prevalent in the developed 
world, with more than 2% of the adult population (nearly 5.5 million Americans) 
estimated to suffer from them2. However, peanuts are especially disconcerting because of 
the low potential for patient to outgrow the condition. Common allergies to foods are 
likely to be outgrown or tolerated once the patient reaches adulthood, however an allergy 
to peanuts is not ameliorated with age and is virtually a life-long condition3. Peanut 
allergies are severe because they can sometime cause death almost immediately due to 
fatal anaphylaxis4. Widespread application and use of peanuts throughout the world pose 
an inescapable risk to patients, currently no preemptive treatments exist but to avoid 
exposure to peanuts altogether. Among all allergies, a peanut allergy is the most severe 
and widespread. It is believed that 1.3% of the adult American population and 0.5% of 
children under 4 years old currently suffer from allergies to peanuts2. 
IgE antibodies have an important role in allergic responses within the body. These 
antibodies are significant because, in the presence of an allergen, they promote mast cell 
degranulation. The observed symptoms of an allergic reaction are the results of mast cell 
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degranulation in the body. Degranulation is the term given when mast cells release 
mediator molecules such as leukotrienes, prostaglandins, and histamines5, 6. The medical 
condition used to define a severe allergic reaction is anaphylaxis. Anaphylaxis is 
characterized as an over exaggerated immune response as the body’s chief reaction 
towards the presence of the absorption of food allergen proteins6. Food induced 
anaphylaxis can occur within only a few minutes after exposure. Anaphylaxis is a 
medical emergency that requires treatment usually with an epinephrine injector possibly 
followed by several doses of steroid medications - it is often necessary for the patient to 
visit the emergency room as well for evaluation6. Food-induced anaphylaxis is a life-
threatening condition where exposed, allergic individuals experience symptoms targeted 
toward single or even multiple body systems and can lead the system to be severely 
compromised as a result6. Symptoms of anaphylaxis can be localized but eventually 
become pervasive and detrimental as time passes without treatment. Patients who are 
unlucky enough to come into contact with their allergen (complete ingestion not always 
necessary to provoke a response) experience a rapid onset of symptoms that lead to 
immediate health decline and, if untreated, sudden death. Localized symptoms include 
gastrointestinal pain as a result of inflammation of the GI tract, difficulty breathing or 
difficulty getting enough air into the lungs usually caused by airway organs becoming 
constricted and closed off - this is usually identified by healthcare providers if wheezing 
is present6. Other noticeable symptoms include rash; swelling of the face, extremities, or 
other areas of the body; or a severe drop in blood pressure resulting in dizziness 
eventually resulting in the patient losing consciousness5. 
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Immunoglobulin E (IgE) and Immunoglobulin G (IgG) antibodies are specifically 
important in the discussion of peanut allergies because of their allergen binding affinities 
and for the roles they play in eliciting an over exaggerated immune response. Binding 
affinity of IgE antibody to a specific allergen is directly related to the occurrence of an 
allergic episode in the presence of the allergen protein. An allergen that is bound to IgE 
antibodies almost instantly produces an immune response and symptoms consistent with 
anaphylaxis and anaphylactic shock5. Allergen sensitivity, the body’s overall sensitivity 
to an allergen and likelihood of producing an allergic episode, is understood to be directly 
related to the quantity of IgE specific antibodies currently within the body7. It is believed 
that IgG antibodies do not play a role in eliciting an allergic attack but are just as 
sensitive to the allergens compared with IgE antibodies. IgG antibodies act to safely and 
effectively remove the peanut allergen from the body without eliciting an allergic 
response. Other components and functions of the immune system exist that aid in 
desensitization, however the exact mechanism is not well understood5, 6. 
The following cascade comes from the current understanding of allergen immune 
reactions: upon exposure, an allergen enters the body and immediately comes into contact 
with the dendritic cell prior to promoting TH0 cell conversion8. TH0 cells are converted 
by the allergen activated dendritic cells. TH0 cells are converted into either TH1 or TH2 
cells, depending on which cell differentiates the TH1 or TH2 cells then travel to the B 
cells. The B cells then produce either IgG or IgE antibodies. TH2 cells produce IgE 
antibodies, TH1 cells produce IgG antibodies8. Mast cells are also important because they 
produce the usual immune response as well as the symptoms commonly associated with 
allergic reactions. The specific role mast cells have in producing an allergic response is 
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still not completely understood, but there is an evidence to support the presence of IgE 
receptors on the surfaces of mast cells, which when activated by allergen linked IgE 
allow the mast cells to produce histamines, prostaglandins, leukotrienes, and cytokines. 
In other words, when IgE antibodies are reacted with an allergen, antibodies can then 
bind to the membrane receptors on the surface of the mast cells which leads to a reaction 
cascade within mast cells leading to degranulation5, 6, 8. Degranulation is the process by 
which mast cells release mediator molecules into the extracellular space. When the 
mediator molecules come into contact with membranes of nearby cells and tissues the 
cells undergo self-destructive reactions usually local apoptosis directly resulting in 
irritation persistent in the region of the body where the reaction occurred5, 6, 8. There are a 
few other degradation pathways not discussed here that carry out immune responses to 
allergens, but the pathway described above is the most significant and potentially lethal to 
patients. 
When the allergen enters the body the cross-linking of allergens to receptor bound 
IgE occurs and this is one of the leading causes for mast cell degranulation. 
Degranulation occurs when the mast cell releases prostaglandins, cytokines, histamines, 
and leukotrienes into the body; collectively these are known as mediator molecules. 
When nearby cells come into contact with these mediator molecules they can undergo 
apoptosis which leads to physiological symptoms of allergies e.g. difficulty breathing due 
to apoptosis of bronchial epithelial cells. The receptor FcyRIIB is known to crosslink 
receptor bound IgE with allergens, however this receptor is also known to crosslink 
allergen bound IgG as well Burton9. IgG is an antibody molecule that has the ability to 
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compete with IgE for binding and in cases where IgG is present there is less binding of 
IgE5, 6, 8. 
Unfortunately, it is possible for patients to suffer from polysensitization in which 
multiple cross reactions occur increasing the severity and even the occurrence of an 
allergic reaction. In other words, Ara h 2 sensitized antibodies are also known to cross 
react with different additional allergens therefore increasing the probability of a reaction 
if the patient is exposed to peanuts in general. Reactions to Ara h 1 and/or Ara h 3 
antigens in addition to Ara h 2 are typically predictive of more severe allergic reactions10, 
11. 
Aside from allergenicity, allergens also have antigenicity that can be disrupted, 
usually referred to as immunogenicity. Immunogenicity is the ability to recognize an 
allergen as a foreign substance, this is not the same as allergenicity because 
immunogenicity is not always associated with production of an allergic response12. If an 
allergen produces an immune response but loses the ability to produce an allergenic 
response then tolerance towards the allergen can be promoted without the threat of 
anaphylaxis. This can be achieved through chemical, mechanical, or even with the use of 
radiation (e.g. microwave)13, 14, 15, 16. By definition this is referred to as an allergoid, 
which is an antigen with reduced allergenicity and maintained immunogenicity17. An 
allergoid could be an essential component making up a potential vaccine designed to be 
exposed to patients. The synthesis and characterization of a viable allergoid is the first 
step in the development of an effective and safe vaccine to promote tolerance in patients 




IgE epitopes on the surface of peanut allergen proteins, like those present on the 
surface of Ara h 2, can become disrupted through chemical modification and could result 
in a lower affinity or complete loss of affinity to IgE sensitive antibodies18. 
Circumventing IgE binding could result in an increase in the degradation pathways 
responsible for digesting peanut allergens without harmful symptoms. This understanding 
is consistent with the findings of a clinical study where 21.5% of peanut allergic patients 
outgrew their condition after peanut challenges administered to patients with already low 
peanut IgE levels in the blood19. Peanut allergies are harmful to hypersensitive patients 
because of the major allergen protein, Ara h 2, and its resistance to chemical modification 
within the body. If the proper conditions are determined, chemically modifying the 
peanut allergen protein could be a simple and effective technique to develop a treatment 
for peanut allergies.  
Currently, the only treatments available are post-occurrence treatments, which are 
usually given to patients after they are exposed to the allergen and the allergen is already 
ingested. Unless a pre-reaction treatment is developed, healthcare providers are limited to 
only emergency treatments given after allergen exposure and advising patients to abstain 
from peanuts altogether - and that’s it. Proper prevention is the only definitive measure to 
lower the possibility of an allergic reaction to peanuts. Avoiding peanut products 
altogether is currently the only guaranteed way to prevent an allergic reaction. Patients 
need to develop an alertness against foods that could contain peanuts to avoid 
accidentally exposing themselves to the allergen. Patients are often burdened with this 
condition because of the required vigilance needed of them in questioning how 
everything they eat is prepared (e.g. when going out to dinner the allergic patron may 
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need to be reassured by the chef who prepared the meal of the absence of any remnants of 
peanut products). Care plans are often needed to be prepared in the event of an exposure 
to the allergen. The care plan is needed to be understood by anyone who is looking after 
an allergic child or even an allergic adult. Caring for a child who is allergic to peanuts is 
a large responsibility and requires guardians to ensure the child understands their own 
emergency plan and what to do in the event of an emergency, in most cases remaining 
calm is the best way to care for someone having an allergic reaction (if adrenaline is 
unavailable) before advanced help arrives. It is also usually recommended by healthcare 
providers that allergic individuals wear a medical emergency identification bracelet or 
necklace so that lay responders can be aware of their condition in the event of an 
exposure.  
Even strict avoidance to peanuts is difficult, most of the time the ingestion is 
accidental. Allergic individuals always live in fear of accidental exposure and the 
possibility of a server allergic reaction. Patients with peanut allergies or any other food 
allergies are usually not limited to being allergic to one allergen e.g. peanuts, in fact they 
commonly have allergies to a whole host of tree nuts such almonds and walnuts (for 
peanut allergies). Therefore, the patient needs to avoid related foods as well as the 
specific allergy food.  
Areas of Research 
Peanut allergies are concerning because public health related research shows a 
significant increase in prevalence of these allergies within the U.S. over the last decade20. 
Unfortunately, the exact cause for an individual to become sensitized (allergic) to peanuts 
is not completely understood, however there are several literature supported theories 
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available. There is evidence supporting the proposition that patient sensitization occurs at 
a young age as a result of breastfeeding using milk containing trace amounts of allergen 
proteins7, 21, 22. As a rationale to this sensitization theory Jarrett E E.21 hypothesized 
stimulation of helper T cells promotes IgE production, occurring in the presence of low 
initial antigen doses compared to high initial antigen doses in which case she 
hypothesized the antigen would actually stimulate suppressor T-cells inhibiting IgE 
production. Coupled with this theory, the research by Hourihane et al.23 helps explain the 
increased prevalence of peanut allergies in westernized countries.  Although their study 
did not control for recall bias, the mothers of children allergic to peanuts and age 5 years 
old or younger were significantly more likely than mothers of older children to have 
eaten peanuts regularly while pregnant or breastfeeding23. The increasing trend for 
mothers to consume peanuts while pregnant shouldn't be overlooked since it directly 
correlates with the outcome of having a child sensitized to peanuts (prior to their first 
peanut exposure) and also correlates with the overall increase in number of patients 
allergic to peanuts. 
Currently, allergen-specific immunotherapy (SIT) is the only treatment able to 
cure allergic diseases and has been shown to be successful in treatment of insect venom 
allergy and in patients suffering from allergic rhinitis or rhinoconjunctivitis24. 
Immunotherapy treatments are well supported and understood, however desensitizing 
patients to a dangerous allergen poses a threat to the patient’s safety that cannot be 
overlooked. Desensitizing patients to a dangerous allergen (i.e. no longer sensitized to the 
antigen) needs to be a careful process. Jarret’s theory proposes that exposing patients to 
substantial allergen quantities stimulates suppressor T-cells within the body, and 
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promotes desensitization. This theory is consistent with the outcome of patients who were 
treated with allergen specific immunotherapy using insect venom allergens which 
ultimately lead to a cure of the allergy24. However, a method to safely expose patients to 
large quantities of otherwise harmful peanut allergens is not well understood and requires 
further exploration. 
Among the research conducted around peanut allergies, a group of Australian 
researchers identified a type of oral immunotherapy that was effective in treating children 
with peanut allergies. Probiotic and peanut oral immunotherapy (PPOIT) was effective in 
inducing possible sustained unresponsiveness and immune changes that suggest 
modulation of the peanut-specific immune response in children with peanut allergy25. 62 
children, as a part of a clinical study, were exposed over a duration of 18 months to a 
minimal amount of peanut protein sample daily that also contained the probiotic 
lactobacillus rhamnose, in extremely high quantities. Remarkably the research concluded 
that over 80% of the study participants achieved possible sustained unresponsiveness to 
peanuts25. The probiotic was believed to have aided the immune system in developing a 
protective response preventing the usual aggravated allergic response25. This altered 
immune response to the peanut protein presents potential investigational treatments of 
peanut allergies and could lead to the development of an overall cure. However, the 
modified allergen has not been evaluated yet for prolonged effectiveness so the return of 
usual symptoms still remains a possible concern to be studied25. 
 Major peanut allergen protein Ara h 2 has been observed to produce severe 
allergic responses when exposed to endogenous antibodies26, 27. Life-threatening 
conditions such as anaphylaxis could be the result in allergic individuals who are not 
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treated immediately after exposure to this specific allergen6. Currently, there is little that 
can be done to preemptively treat allergic episodes resulting from peanut allergens. 
Identifying a safe, and preferably uncomplicated, method of exposing patients to the 
peanut allergen to increase the body’s tolerance to the allergen is significant to increasing 
understanding and in the overall treatment of these allergies. More research is also 
necessary to increase understanding of the chemical properties of Ara h 2 and its role in 

















Major Peanut Allergen Ara h 2 Isolation and Identification 
Ara h 2 is one of the known allergens in peanuts that causes the most severe 
reactions associated with peanut allergies. The peanut kernel contains 11 major allergen 
proteins that on their own elicit an allergic response27. Of the 11 peanut allergens, Ara h 2 
has consistently shown to be the most significant. More than 90% of patients with peanut 
related allergies contain IgE antibodies with remarkably high binding affinity to Ara h 
227. Ara h 2 has also shown to be seemingly resistant to most protein degradative 
processes. For example, heating Ara h 2 actually increases its ability to elicit an allergic 
response within the body, and exposing Ara h 2 to conditions consistent with the stomach 
and GI tract showed to have little to no effect on reducing the protein's overall 
allergenicity28, 29, 30, 31, 32. 
Ara h 2 appears on SDS-PAGE as a doublet with a molecular weight between 17-
19kDa. Ara h 2 is an allergen protein that is made up of 157 amino acids Figure 133. 
Isolating Ara h 2 is the essential initial step in the synthesis of the potential allergoid. 
However, prior to immunoassays, experiments designed to observe the presence of 
structural changes to the allergen are needed. To perform experiments focused on the 
structure of Ara h 2, isolating Ara h 2 is important to avoid the presence of additional 
proteins in solution that could lead to variable results. A robust, reliable, and efficient 










Figure 1. Ara h 2 amino acid sequence. Ara h 2 amino acid sequence represented as 




Synthesizing an allergoid from Ara h 2 is the major objective of this research 
followed by characterizing its in-vitro immune affinity prior to in-vivo immunoassays. In 
addition to in-vitro experiments, reproducing the allergoid synthesis reaction is a strong 
factor in determining whether or not the product is ready to be exposed to biological 
subjects (small and large animals). Exposing animal subjects requires highly pure 
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allergoid samples. For example, if impurities do exist as an essential factor to the 
formation of the allergoid then reproducing the allergoid reaction would not be possible 
without the presence of the original impurity, even if impurities existed that do not 
benefit the overall allergoid reaction there is still potential for the impurity to alter the 
overall effectiveness of the product as a drug once administered to subjects leading to 
unpredictable and even dangerous outcomes. The most effective method for producing an 
allergoid consistently, that displays no uncertainty in usability and effectiveness, remains 
contingent on how well the synthesis reagents were isolated. 
Materials and Methods 
Sample Preparation 
Ara h 2 was purified following the method by Sen34 with additional modifications 
made to the procedure. Peanut kernels (Arachis hypogaea L., Florunner cultivar) 
purchased from Good Earth Peanut company were exposed to liquid nitrogen and the 
frozen kernels were then crushed by mortar and pestle prior to being defatted three times 
in a Soxhlet extractor starting with petroleum ether for the first two exchanges and then 
finally using chloroform for the last reflux. The defatted peanut kernels were pulverized 
to a fine flour. The defatted peanut flour was then added to a TBS buffer (pH 8.3, 65 mM 
Tris-base, 1 mM EDTA, 1 mM PMSF and 200 mM NaCl) and stirred in TBS for 1 hour 
on ice at 4° C. After stirring the peanut powder in the TBS buffer for about 5 minutes, the 
extract was sonicated (Sonics Vibra-Cell VCX-600) at 40% for 2 min over ice to increase 
the chances of extracting intracellular proteins into the sample solution, through non-
ionizing vibration. The extract was then cleared by filtration through six layers of 
cheesecloth and then centrifugation at 30,000 × g for 30 min at 4° C. Ammonium sulfate 
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was used to fraction the supernatant. Ammonium sulfate was added to bring the solution 
to 40% saturation, the sample was then centrifuged at 30,000 × g for 30 min at 4° C and 
the supernatant was collected and the pellet was discarded. Ammonium sulfate was added 
again to bring the solution to 70% saturation and the sample was centrifuged at 30,000 × 
g for 30 min at 4° C and the pellets was collected and the supernatant was discarded. The 
pellets were resuspended in a total of 10 mL of TBS buffer (pH 8.3, 65 mM Tris-base, 1 
mM EDTA, 1 mM PMSF) and sonicated on ice for 20 seconds at 39% power. 
Undissolved particles were removed by centrifugation (3,000 × g for 15 min).  
Allergen purification was accomplished using a series of chromatography 
columns based on ionic charge and hydrophobicity. Q-sepharose column prepared with 
100mL of resin to achieve the desired column bed volume of 2.5cm X 30cm. The protein 
sample was applied to the Q-sepharose anion exchange column which was equilibrated 
with pH 8.3 65 mM Tris buffer, 1 mM EDTA and1 mM PMSF prior to loading protein 
sample. After washing the column with 200 mL of Tris buffer containing 40 mM NaCl, 
bound proteins were eluted using a 400 mL linear salt gradient (40 mM - 500 mM NaCl, 
65 mM Tris-HCl, 1 mM EDTA, 1 mM PMSF at pH 8.3) at 2 mL/min flow rate. 2.5 ml 
fractions were collected, analyzed with coomassie dye 50uL: 150uL (protein: dye) and 
then analyzed by SDS-PAGE. Pooled fractions containing Ara h 2 were dialyzed 
overnight at 4°C against 15 mM ammonium bicarbonate (pH 7.0) dialysis buffer 





Samples solubilized in sample loading buffer (1.5 mL of pH 6.8, 1 M Tris-HCl, 
1.5 mL of 1 M dithiothreitol, 0.3 g of sodium dodecyl sulfate, 0.015 g of bromophenol 
blue, 1.2 mL of glycerol - Final volume of 7.5mL). Samples solubilized by combining 
10uL of 40% diluted sample (dilution with 25mM Tris buffer at pH 10.5) with 10uL of 
2X sample buffer. Samples vortexed slowly, to avoid splashing, and then were heated in 
boiling water (100° C) for 5 minutes. Samples were vortexed on setting number 8 (after 
heating) and centrifuged at 3,000 × g for 5-10 seconds at room temperature (to 
accumulate sample toward the bottom of the centrifuge tube, and away from the container 
walls) prior to loading samples onto SDS-PAGE gel. Tris glycine (4-20%) SDS-PAGE 
gels (manufactured by BioRad) were used. A 10uL of sample volume was loaded into 
each well of the SDS-PAGE gel. A 10uL of molecular weight standard was loaded onto 
the gel only after protein samples were loaded. The gel was allowed to run at 120V until 
enough time passed for the proteins to run to the bottom of the gel. The gel was then 
stained in a coomassie dye and methanol based staining solution (1.25g Coomassie R-
250, 30% methanol, and 10% acetic acid). After approximately 24 hours in the staining 
solution, the gel was then destained to remove excess stain using a water based destaining 
solution (30% methanol and 10% acetic acid). 
Results 
Prior to running samples on SDS-PAGE, samples were evaluated for protein 
content by commassie dye analysis. Results using coomassie dye can be found in Figure 
2 and Figure 3. Figure 2 and Figure 3 compare the results of different salt concentrations 
in preparing the protein elution gradients. Figure 2 shows the result of running a strong 
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elution gradient of 40mM – 1M NaCl (200mL) and resulted in eluted proteins being 
heavily concentrated in the middle of the gradient. Whereas Figure 3 displays elution 
results after running a gradient of 40mM – 140mM NaCl (200mL) it appears to suggest a 
























Indicates where Ara h 2 major allergen 





















Figure 2. Coomassie dye analysis of fractions following the Q-column, eluted with 40 
mM – 1 M NaCl gradient at 2mL/min 2mL fraction volume  (65 mM Tris buffer, 1 mM 
EDTA, and 1 mM PMSF). Every 3rd sample out of 144 total collected samples was 

























Figure 3. Coomassie dye analysis of fractions following the Q-column, eluted with 40 - 
140mM NaCl gradient @ 2mL/min 2mL fraction volume  (65 mM Tris buffer, 1 mM 
EDTA, and 1 mM PMSF). Every 3rd sample out of 144 total collected samples was 




 Indicates where Ara h 2 major allergen 
was found.  
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Discussion of Allergen Purification 
According to Sen34 defatting peanut kernels can be achieved by refluxing petroleum ether 
over the sample. According to Packer35 defatting samples not completely can result in 
poor extraction efficiency. Therefore, this step was modified, petroleum ether was used to 
start, which has a polarity index of 0.1, but ultimately the reflux was finished with 
chloroform that has a polarity index of 4.1 to extract less non-polar materials away from 
the peanut kernels. Following ammonium sulfate precipitation pellets should be dissolved 
completely to allow for complete separation. Our findings led us to determine that 40 
mM – 500 mM NaCl was the optimal gradient to be used for Ara h 2 elution from the Q-
sepharose column observed by commassie dye analysis (Figure 4) and SDS-PAGE 
analysis (Figure 5). This determination was made because of the inefficiency in eluting a 
mixture of unseparated proteins all at once (Figure 2) and in eluting the desired proteins 
too widely to be efficiently collected (Figure 3). Gradients that contained larger or 
smaller margins between concentrations of NaCl, than described above, were generally 
not well suited and caused inconclusive and inconsistent results. Also, to be noted, since 
Ara h 2 is only 17kDa in size, 4-20% Tris-glycine gradient gels (manufactured by 
BioRad) were used for precise separation of protein. Other gradient gels were not 
individually studied since additional gradient gels were not well documented by the 


























Figure 4. Coomassie dye analysis of all 144 fractions after running sample on Q-
sepharose column eluted at 40 - 500 mM NaCl, 65 mM Tris buffer, 1 mM EDTA, and 1 
mM PMSF. Well # 1 (1st fraction) located in top left well. Red lines are indicative Ara h 
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Figure 5. SDS-PAGE gel of specified fractions, which indicated protein after using 
coomassie dye, of sample after running sample on the Q-sepharose column eluted at 40 - 
500 mM NaCl, 65 mM Tris buffer, 1 mM EDTA, and 1 mM PMSF. 
 











Protein Chemical Modification-Lead Compound Assessment 
The major peanut allergens Ara h 2 and Ara h 6 were the focus of the research 
study completed by Koppelman29 because of the apparent synergy of these allergens in 
eliciting an allergic response. Researchers confirmed Ara h 2 and Ara h 6 have an integral 
role in the biological mechanism leading to an allergic reaction, however, by reducing the 
allergens and subsequently chemically modifying [alkylating] them with glutaraldehyde 
the researchers determined that it was possible to alter the allergen’s secondary and 
tertiary structures. Presuming allergen structure was necessary to allergen function, 
researchers designed a series of clinical studies to further evaluate the newly, chemically 
synthesized allergen products. Again, using children as participants, patients were 
injected with small doses of the chemically modified allergen sample. The participants 
exposed to the chemically modified samples displayed later time activated reactions and 
overall decreased response when exposed to the native allergens. The researchers 
concluded this to be a viable method in desensitizing patients to their allergen and 
because of the levels of effectiveness observed should serve as another potential 
candidate for peanut allergy therapy. This finding (glutaraldehyde being a necessary 
protein modifier) was also identified by Park36; Silva37; and Stanić-Vučinić38 however 
these groups of researchers experimented with proteins and allergens outside of Ara h 2. 
Proteins can crosslink through glycation reactions, and undergo physical 
structural changes39, 40, 41. Carbonyl containing reagents were previously identified as 
capable of eliciting protein cross-linking. According to Acharya42 the protein RNase was 
successfully cross-linked using glyceraldehyde. The experiment called for 20 mM of 
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glyceraldehyde at 7.4 pH and 37° C. The formation of crosslinks with RNase using 
glyceraldehyde was concluded to be analogous to nonenzymic glycation reactions. In 
other words, by using (carbonyl containing) aldehydes it is possible to form advanced 
glycation end products i.e. cross-linked structural proteins Acharya42. 
There are several studies in the literature that can be referred to for support where 
several reagents were evaluated for success in modifying Ara h 2 and in eliminating or at 
least significantly reducing allergenicity. Experiments conducted by Chung43 displayed 
significant decrease in allergenicity of peanut allergens using phenolic compounds. 
According to Chung44 tannic acid is successful at significantly reducing allergenicity of 
peanut allergens. One study actually concluded that using ferulic acid actually increases 
the likelihood of Ara h 2 antibody binding45. 
According to Chung46 caffeic acid and chlorogenic acid are examples of chemical 
reagents that can be oxidized to form quinone derivatives susceptible to bonding to free 
amine groups, sulfhydryl groups, and tryptophan groups and capable of catalyzing a 
crosslink between two separate complete proteins. Caffeic acid and chlorogenic acid have 
been studied for their potential to modify the allergen protein and have successfully 
formed Ara h 2 allergoids. From the experiments carried out by Chung46 oxidizing caffeic 
acid require a basic environment above pH 10 to form the reactive quinone necessary to 
potentiate the crosslinking reaction. Caffeic acid and chlorogenic acid are just two 
examples of chemical modification reagents, where it is important the proteins being 
crosslinked are examined for the appropriate amino acid content needed to catalyze the 
reaction. Since these chemical reagents were found to be successful by Chung46 we 
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proposed the possibility of reagents closely related to these molecules also containing 
potential reactivity with Ara h 2 as well. 
Proteins capable of crosslinking reactions, catalyzed by arginine targeting 
chemical reagents, contain roughly 5% arginine residues47. The quantity of arginine 
residues in Ara h 2 is approximately 12%33. The ketone aldehyde group of the compound 
Phenylglyoxal acts as an oxidizing agent and targets arginine residues in proteins48. The 
guanidine group of arginine interacts with phenylglyoxal and forms heterocyclic 
condensation products which could potentially promote a structural change to occur in 
Ara h 2 which results in the crosslinking between two reactive Ara h 2 proteins48. 
Diketone reacting groups of aromatic molecules also react well with arginine amino acids 
and have been studied to promote crosslinking in proteins. Based on this understanding, 
the compounds phenylglyoxal monohydrate and its derivatives4-fluorophenylglyoxal 
hydrate, 4-methoxyphenylgyoxal hydrate, 2,3-butandione, 2,3-hexandione, 3,4-
hexanedione, and 2,3-heptanedione were examined to determine their ability and 
efficiency in crosslinking Ara h 2. Figure 11 shows a highly simplified proposed reaction 
mechanism that utilizes arginine residues of Ara h 2 to promote a crosslinking reaction to 
occur. 
Materials and Methods 
Chemically Crosslinking Ara h 2 
Allergoid synthesis reactions were prepared in sealed 1.5 mL centrifuge tubes. 
The cone shaped centrifuge tubes allowed reaction mixture to pool near the base of the 
container for simple extraction by micropipette. Allergoid synthesis reagents were 
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dissolved in 25 mM Tris-base buffer at pH 10.5, using additional solvents when needed 
(Figure 9) and serial diluted to desired concentrations. 
Lyophilized protein was dissolved into 25 mM Tris buffer at pH 10.5 at a working 
protein concentration of approximately 1-2 mg/mL. Ara h 2 protein concentration was 
quantified against a BSA (bovine serum albumin) standard curve. To prepare the BSA 
standard curve the following BSA dilutions were prepared (according to the manufacturer 
ThermoFisher Scientific): 2000, 1500, 1000, 750, 500, 250, 125, and 25ug/mL, and 
0ng/mL for blank control. The BSA dilutions were prepared using 25 mM Tris-base 
buffer at 10.5 pH (same buffer used to dissolve Ara h 2). 5uL of each BSA stock dilution 
was added to the appropriate well on a 96-well microplate. BSA stock dilutions were 
added to the microplate, three trial replicates evaluated. A 5uL of the unknown 
concentration of Ara h 2 sample was added to 3 clean wells on the microplate (three trial 
replicates evaluated). 250uL of the coomassie dye reagent was then added to each well 
containing unknown or stock samples and the microplate was allowed to mix on shaker 
for 30 seconds prior to measuring absorbance. Stock and unknown absorbance was read 
with a microplate reader using UV-visible light at 595 nm wavelength. The average 
absorbance at 595 nm for each BSA standard dilution vs. its concentration in ug/mL was 
plotted after correcting for the blank (0ng/mL concentration) for each concentration. The 
BSA standard curve was then used to determine the protein concentration of the unknown 
Ara h 2 sample.  
Stock solutions of the modifying reagents were prepared using buffer and any 
additional solvent(s) necessary to dissolve the specific reagent. The desired 
concentrations for the stock solutions were prepared by serial dilution making sure to 
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keep the overall solvent concentration consistent for each reagent concentration. Once 
stock reagent solutions were prepared, stock Ara h 2 solutions were prepared using 
2mg/mL protein concentration (1mg/mL final protein concentration after reaction). 
Finally, we combined the stock reagents with the Ara h 2 solution by adding an aliquot of 
each stock concentration into the tube already containing Ara h 2 protein (equal volume 
to volume ratio). The centrifuge tubes were then sealed off and incubated at the 
conditions described above. A graphic of the modification procedure can be found in 
Figure 6. 
Several reagents were evaluated for allergoid synthesis potential (Table 2 and 
Table 3). The evaluated reagents were reacted with Ara h 2 under various conditions to 
determine reaction viability. The evaluated conditions included variations in reaction 
buffer, reaction buffer pH, exposing the reaction mixture to agitation vs. non-agitation, 
reaction temperature, concentration of reagent exposed to protein, and time exposed to 
protein evaluated to understand which conditions were ultimately most effective in 













Figure 6. 3-step infographic procedure used to chemically modify the allergen. 
Depending on the reagent used specific solvents were required to fully dissolve the 
reagent into solution. Following the solvent concentration guidelines listed above for the 
specific reagent to be dissolved. It is necessary to keep the solvent concentration 
consistent for all reagent serial dilutions. The highest reagent concentration to be 
evaluated was determined and then multiplied by two because the prepared stock 
concentrations are actually 2X that of the prepared working concentrations. 1mL of 
solvent/buffer solution was used to prepare the first reagent concentration within a 1.5 
mL centrifuge tube then vortexed until reagent dissolved completely. Serial dilutions of 
first reagent concentration prepared by adding 500 uL of solvent/buffer to 5-10 empty 1.5 
mL centrifuge tubes. 500 uL of original reagent solution was combined with 
solvent/buffer within one of the prepared centrifuge tubes and mixed until homogeneous. 
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Allergoid synthesis reagent candidates effective promoting a reaction with Ara h 2. 
 






Centrifuge tubes were used to prepare the protein modification reactions. The 
desired volume of reagent was added to an equal volume of protein to start the allergoid 
reaction. The reaction solutions were incubated and agitated for 30 days at 37° C. 
Reactions were carried out in a rotating incubator rotating 360 degrees at a speed of 5 
RPM. After the desired time had passed, samples were evaluated by SDS-PAGE.  
Excess modification reagent was removed by dialysis. Samples were dialyzed 
against 3L of 15mM ammonium bicarbonate buffer at pH 7.4 in a 0.1 - 0.5 mL dialysis 
cassette (MWCO 20kDa). Using a 1 mL syringe, separate dialysis cassettes were 
individually loaded with modifications samples at different reagent concentrations until 
all concentrations had been effectively dialyzed. Dialysis buffer exchanges were carried 
out until samples appeared clear in color and no longer exhibited the original reagent 
influenced color. Once modifying reagents were removed from the sample, modified 
protein samples were lyophilized and stored at -70° C. 
Results 
According to Lundblad47 borate buffer at “basic pH” should facilitate protein 
crosslinking reactions when solubilized proteins are exposed to diketone crosslinking 
reagents. However, this is not reflected in our data. Figure 8 displays several SDS-PAGE 
gels of unsuccessful allergoid reactions using borate buffer at different concentrations of 
reagent. This is significant because literature has cited borate buffer as being an effective 
buffer that should be used in protein modification reactions when using the reagents that 
were used here.   
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Ara h 2 was exposed to varying concentrations of Phenylglyoxal monohydrate, 4-
Fluorophenylglyoxal hydrate, 4-methoxyphenylgyoxal hydrate, 2,3-Butandione, 2,3-
Hexandione, 3,4-Hexanedione, and 2,3-Heptanedione. Allergoids were reproducibly 
produced by using Tris-base buffer at pH 10.5 and sample agitation at 5 RPM by 
rotisserie at 37° C.   Instead of the usual doublet band observation around 17kDa and 
19kDa (in the case of native un-modified Ara h 2) a smearing pattern occurred between 
and around the doublet bands which indicated some degree of protein modification to the 
allergen monomer. In addition to the simple allergen protein modifications, where the 
monomer was still the only oligomer present, the results of higher intensity modification 
reactions were also observed. These high intensity reactions resulted in an observed 
possible crosslink between allergen proteins by the formation of multiple oligomers, 
appearing on the SDS-PAGE as dimers and even trimers as shown in Figure 9. 
Discussions 
The potential allergoid, the new product formed between Ara h 2 and the 
modification reagent, is prepared in aqueous buffers. The reaction solution is a mixture of 
the newly formed allergoid, un-reacted Ara h 2, reaction buffer, and reagent dissolving 
solvent. Ara h 2 is an aqueous soluble protein, however most of the modification reagents 
used were not soluble in water, so a range of solvents were needed to dissolved and 
expose these reagents. Some of the reagents evaluated did not react well with Ara h 2, 
this failure in reactivity may be attributed to reagent solubility or an incompatibility 
between the solvents used and the reagent. 
To determine which reaction conditions consistently produced a positive potential 
allergoid formation, from natural Ara h 2 allergen, variations of these conditions were 
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examined. However, for consistent results we found that using a simple 25 mM Tris-base 
buffer worked well. 
Most of the reagents used were completely insoluble in water based buffers, so 
organic solvents were necessary. However, to avoid damaging or altering the Ara h 2 
protein through the use of organic solvents alone it was also necessary to use the least 
amount of solvent needed to fully dissolve the reagent in the buffer solution. To do this, 
several trials were prepared where a fixed amount of crosslinking/modification reagent 
was weighed out and then dissolved in the lowest possible volume of a solvent, finally 
buffer was added to the reagent-solvent mixture to determine if the reagent would remain 
soluble. Frequently the reagent used would precipitate of the solution after being mixed 
with the buffer. After several attempts to determine the solubility of the desired reagent 
quantity, varying the concentrations of reagent and organic solvents used (for each 
reagent evaluated), the minimum amount of organic solvent required to solubilize the 
reagent was determined. After this was determined we could then add the reagent to the 
protein and begin the modification procedure. 
Previously it was determined that agitation during incubation with the 
crosslinking reagent was important for efficient reactivity. The reactor used in the lab was 
constructed from a rotisserie style incubator device, allowing control of reaction 
temperature. High temperatures are well known to increase the likelihood of collisions 
between reacting molecules in solution, we found that incubating at 37 degrees Celsius 
on a constant rotation speed of 5 RPM produced consistent reaction outcomes. The 
rotating reactor allowed for the modification reaction to occur in a much shorter duration 
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of time, which proved to be much more efficient and even more effective than the stand 
alone stationary incubator.  
Several reagents were attempted for allergoid synthesis potential and the complete 
list can be found in Table 2 and Table 3. However, phenylglyoxal monohydrate 
derivatives and simple diketone containing molecules were ultimately identified to 
generate strong chemical crosslinking of Ara h 2. Based on these results, Ara h 2 






Figure 7. Methods for dissolving allergoid synthesis reagent candidate compounds in 











Figure 8. SDS-PAGE of allergoid synthesis reagent candidates using borate buffer under 










Figure 9. SDS-PAGE of successful allergoid synthesis reactions, reacted under basic 







Allergoid Viability Determination by In-Vitro Assay 
A modified protein sample that displays a shift in mobility observed by SDS-
PAGE is a necessary initial confirmation that the protein sample deserves further 
evaluation for its immune affinity. Unfortunately, however, a shift in mobility is not 
sufficient to identify a modified allergen protein as a potential and useful allergoid. 
Further experiments are required before any assumptions can be made about the sample. 
Using specialized experiments founded in immunology, it may be possible to further 
interpret if a potential allergoid product was actually formed. Immunoassays specific to 
the native allergen are necessary to provide additional characterization details for the 
allergoid. These details could include chemical and biological properties. 
An appropriate immunoassay to determine the viability of the formed allergoid is 
a western blot analysis. Western blot exposes the modified allergen to peanut specific IgE 
antibodies to evaluate binding affinity. This immunoassay is based on the understanding 
that IgE antibodies bind to regional protein epitopes that are intact and unshielded. 
Variations to protein solubility can result in alterations to these epitope surfaces, possibly 
due to exchanges between non-polar amino acids and polar amino acids. Surface IgE 
epitopes that are disrupted or shielded, through chemical modification, could result in 
decreased antibody binding affinity. In other words, if there is an observed difference in 
binding affinity between the native allergen and that which was modified then antibodies 
failed to bind to the modified allergen, and therefore resulted in the successful formation 
of a potential allergoid.  
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Materials and Methods 
Preparing pAb for Western Blot analysis 
Our research lab prepared the allergen sample provided to Neo Scientific to raise 
and purify Ara h 2 specific IgE antibodies. IgE antibodies were raised against antigen 
protein Ara h 2 in rabbits to be used in immunoassays. Antigen samples need to be 
approximately 88% pure when raising IgE antibodies to avoid the potential of raising 
antibodies against unknown impurities which could weaken overall affinity to Ara h 2. 
Once the antigen is prepared and the purity is verified, using SDS-PAGE, the antigen can 
then be exposed to rabbit organisms. Approximately 3-4 mL of antigen at a concentration 
of 1-2 mg/mL is needed to prepare the antibodies. This is the process known as 
sensitizing, since the antibodies are being sensitized to the antigen. The antigen is 
exposed to the endogenous immune system of rabbits to form sensitized IgE antibodies. 
After antibody sensitization, the animal is stimulated to produce IgE antibodies in the 
presence of the allergen protein.  Antibodies can then be removed simply by extracting 
the animal’s blood and following up with a series of centrifuge purifications. The impure 
antibody solution is then run on an affinity column to purify and collect only the desired 
antibodies. Finally, a standard curve is used to determine antibody affinity toward the 
antigen protein. 
Western Blot Procedure 
Prior to running the western blot analysis, an SDS-PAGE was completed where 
replicates of the evaluated samples were prepared and run on the same SDS-PAGE gel. 
The first half of the SDS-PAGE gel (lanes 1-6) contained replicate samples of the second 
half of the gel (lanes 7-12). The SDS-PAGE gel was prepared in this way for the purpose 
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of (after electrophoresis) exposing half of the gel to coomassie dye stain and half of the 
gel to western blot analysis to eliminate the possibility of any variations between the two 
samples. After successfully running the SDS-PAGE, the proteins were transferred from 
gel to a cellulose membrane using the semi-dry western blotting technique. To start, 2 
extra thick blotting pads and the cellulose membrane were exposed to transfer buffer (25 
mM Tris buffer, 190 mM glycine, 20% methanol, dH2O to 1000 mL) for 15 minutes. The 
gel was secured on top of the cellulose membrane between two blotting pads. 
Sandwiching the samples to be transferred, the cathode plate assembly was secured to the 
anode plate. The trans-blot semidry apparatus was run for 60 minutes at 15V. The 
cellulose membrane was removed first washed with distilled water prior to being 
immediately exposed to 5% stopping buffer (5% low fat milk in PBST) agitated at room 
temperature for 60 minutes. The cellulose membrane was then washed 5 times with PBS-
T for about 5 minutes each. The membrane was exposed to 10 mL of 1:250 primary IgE 
antibody in 5% stopping buffer and agitated overnight at 4o C. Membrane was then 
washed 5 times with PBS-T for about 5 minutes each. The membrane was then exposed 
to 10 mL of 1:1000 secondary antibody in 5% stopping buffer and agitated at room 
temperature for 60 minutes. Membrane then was washed 5 times with PBS-T for about 5 
minutes each. The membrane was then immediately exposed to 5 mL of 
chemiluminescence substrate. Substrate components were pre-prepared by the 
manufacturer (ThermoFisher). Substrate components consisted of “Substrate A” and 
“Substrate B” which needed to be mixed together prior to exposing to the membrane. 
Substrate A and B were mixed equally, totaling 10 mL. Exposed membrane was then 
incubated for 1 minute at room temperature (exposed to substrate). Photo of western blot 
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was captured using a CD chemi-blot UV camera at normal intensity settings and 30 
seconds exposure. 
Results 
Experiments were completed that exposed IgE antibodies to modified and 
unmodified Ara h 2 to observe if there were any variations in antibody affinity. Figure 10 
displays SDS-PAGE and western blot results of reagent exposed Ara h 2 samples. There 
appears to be visible indication of protein chemical modification of Ara h 2 through 
mobility shift observed by SDS-PAGE analysis. This figure appears to display visible 
smearing and even polymerization dependent on the reagent used. There also appears to 
be a direct correlation between higher reagent concentration exposure and an increased 
susceptibility for the protein to undergo chemical modification. Higher concentrations of 
exposed reagents modified Ara h 2 at higher intensities compared to lower reagent 
concentrations. Western blot analysis of the samples appeared to display decreased 
affinity of IgE antibodies toward the modified Ara h 2 allergen samples. Antibody 
affinity also appeared to be dependent on the concentration of reagent exposed to the Ara 
h 2 protein. 
Discussions 
As we experimented with chemical modifications to Ara h 2 and compared the 
results of formed potential allergoids and unmodified allergens we noticed a visible 
mobility shift by SDS-PAGE that directly correlated with a change in IgE antibody 
binding affinity (Figure 10). A control using bovine serum albumin (BSA) was used to 
identify any imprecise antibody binding and showed to be conclusive in that the 
antibodies were actually specific to Ara h 2. Unmodified Ara h 2 was also used as a 
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control to show the effectiveness of the antibody binding. Figure 10 displays a mobility 
shift of modified Ara h 2, the modified allergen is still visible on the SDS-PAGE even 
after being modified by the specific reagent. However, the western blot analysis shows a 
stark difference between the antibody affinity towards the unmodified control and the 
affinity towards the modified samples. This is evidence that the allergen protein is still 
present in the sample solution but is failed to be detected by the highly specific 
antibodies.  
As Ara h 2 is modified there is a chance of losing the original protein solubility 
character 49. SDS-PAGE cannot determine protein solubility specifically, but a lack of 
visible protein on the SDS-PAGE, especially after protein modification, could be the 
consequence of poorly dissolved protein as a result of the chemical modification. The 
protein allergoid could potentially become so insoluble (compared to the native un-
modified protein) that it could form an aggregate pellet and precipitate out of the sample 
solution 49. If the protein does become so insoluble that it is no longer observable by 
SDS-PAGE, and therefore western blot, attempts to solubilize the protein may be 
necessary so it can be observed by SDS-PAGE and therefore able to be analyzed by 
western blot. The idea that modified Ara h 2 could be less soluble in solution than the 
native Ara h 2 was a reasonable consideration. However, due to time limitations and 
extreme limitations on resources, specifically scarce quantities of allergen protein it was 










Figure 10. SDS-PAGE and ant-Ara h 2 IgE western blot of successful allergoid synthesis 







Overall Allergen Crosslinking Discussion 
Peanut protein Ara h 2 has been observed to produce severe allergic responses 
when exposed to endogenous antibodies. Life-threatening conditions such as anaphylaxis 
could be the result in allergic individuals who are not treated immediately after allergen 
exposure. Currently, there is little that can be done to preemptively treat allergic episodes 
resulting from peanut allergens. More research is necessary to increase understanding of 
the complete role of the peanut allergen and its effects in the body. Identifying a safe 
method of allergen exposure to patients could result in an endogenous immune system 
tolerated to peanuts, and specifically the major peanut allergen Ara h 2. 
The major allergen Ara h 2 was isolated successfully following the procedure 
described in chapter 2. Several reaction conditions were attempted, listed in chapter 3. 
The variables of these conditions that were mostly responsible for generating a positive 
chemical modification reaction with Ara h 2 were determined. Tris-base buffer at 10.5 
pH and at temperature of 37° C on constant rotation facilitated the reaction well. The 
allergoid reaction procedure was then standardized to maintain consistency in reagent 
target screening which allowed for reproducibility and resulted in the identification of 
several vaccine candidate lead compounds. Several novel Ara h 2 allergoid synthesis 
reaction mechanisms were proposed. Since the presence of epitope surfaces are the result 
of the native protein structure, a significant disruption to this structure could lead 
inaccessible or even eliminated epitope surface regions. Protein chemical modification 
was the chief method used to alter the protein structure. According to Feeney50 protein 
chemical modification is an effective method for altering protein structure. Reagents 
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known to react with specific amino acids were used to promote the protein chemical 
modification. SDS-PAGE was used to determine if the chemical modification was 
successful.  
As for protein chemical modification experiments, specifically when using SDS-
PAGE to observe results, the evaluated sample protein may appear at a molecular weight 
different from the native protein, if there is a shift in gel mobility of the protein from the 
native control sample then this could be the first observation of polymerization of the 
protein. Even though it may be too soon to make any type of determination having only 
molecular weight data, the data is still important because of the provided opportunity to 
secure the polymerized samples to be further evaluated using additional experiments that 
could lead to an enhanced understanding of the chemical properties of Ara h 2. 
There were a few significant factors to keep in mind in our attempts to modify the 
allergen. There was always a possibility of altering the allergen’s solubility when 
synthesizing the allergoid thus causing the potentially formed allergoid to be insoluble. 
Solubility changes appeared to occur more quickly at higher reagent concentrations. 
Protein concentration, modification reagent concentration, and reaction conditions with 
each concentration were evaluated thoroughly and in duplicates to determine the most 
effective and direct route to a viable allergoid synthesis. There appeared to be 
relationship between the quantity of reagents used and the overall strength of the 
chemical modification to protein. Ultimately, protein concentrations around 1-2mg/mL 
and chemical reagent concentrations around 50mM appeared to be the most effective in 
modifying Ara h 2. In addition to reagent concentrations, higher pH and warmer 
temperatures appeared to increase the likelihood of a potentially successful reaction. 
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SDS-PAGE was the most effective technique available to us to identify protein 
modification and the viability of the modification at the conditions being tested. There 
always existed the possibility of only partially modifying Ara h 2, resulting in a modified 
allergen protein that still retained IgE excitability potential. Therefore, the attempted 
reaction conditions needed to be well refined to successfully facilitate the desired 
allergoid forming reaction.  
Another important consideration was the solvent (or solvents) used to dissolve 
reagents within the buffer which were limited to a minimum so not to interfere with the 
crosslinking reaction and to avoid any negative and destructive effects to the allergen as a 
whole. The buffer used to maintain the reaction pH was based on the conditions essential 
to the reagent being tested and if Ara h 2 could be safely stored in the specific buffer over 
the duration of time needed to carry out the reaction.  
The validity of the allergen modification reaction was first confirmed through 
mobility shifts that suggested a change in protein molecular weight between the native 
allergen and the allergen exposed to the evaluated compound. The change in molecular 
weight is the initial indicator of a potential change to the epitope surface regions. A 
positive change to the epitope surface regions is presumed to be indicative of a change in 
immune-reactivity as well. A change in immunoreactivity could potentially result in a 
change in how the allergen functions during in-vitro and in-vivo testing. Several 
modification reagents were attempted, the complete list can be found in Table 2 and 
Table 3, however the reagents capable of generating an actual allergoid are discussed in 
further detail here. According to Packer35 proteins capable of crosslinking by chemical 
modification to arginine residues contain roughly 5% arginine. The quantity of arginine 
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residues in Ara h 2 is approximately 12%. The ketone aldehyde group of the compound 
Phenylglyoxal acts as an oxidizing agent and targets arginine residues in proteins. The 
guanidine group of arginine interacts with phenylglyoxal and forms heterocyclic 
condensation products promoting a structural change to occur in Ara h 2 which results in 
the crosslinking between two reactive Ara h 2 proteins. Diketone reacting groups of 
simple organic molecules also react well with arginine amino acids and have been studied 
to promote crosslinking in proteins 35.  
Since phenylglyoxal monohydrate was previously determined to chemically 
crosslink proteins at arginine residues when prepared at pH 10.5, and phenylglyoxal 
monohydrate displayed crosslinking capabilities when exposed to Ara h 2, 4-
Fluorophenylglyoxal hydrate, 3,4-difluorophenylglyoxal hydrate, 4-
methoxyphenylgyoxal hydrate appeared to be good candidates as well for crosslinking 
peanut allergen. Our successful attempts led us to our current understanding that 4-
Fluorophenylglyoxal hydrate and 3,4-difluorophenylglyoxal hydrate could be 
crosslinking Ara h 2 proteins in the same fashion as phenylglyoxal monohydrate where 
the Fluorine(s) group on the aromatic ring could be acting as an electron withdrawing 
group. It could be essential to pull electrons away from the diketone to react effectively to 
Ara h 2. Another explanation could be how effectively the reagents were dissolved in the 
reaction buffer. Each of these reagents was different in terms of solubility which could 
have played a role in overall reactivity as well. There is currently no prior works using 4-
Flurophenylglyoxal hydrate in modifying the peanut allergen protein Ara h 2. No 
associated IgE data could be obtained for 3,4-difluorophenylglyoxal hydrate, due to the 
sample limit in the end. There was no 45 day SDS-PAGE data or IgE data to evaluate, 
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however this modification reagent was effective in modifying Ara h 2 after observing the 
results of resulting sample batches that were completed at another time using a different 
native Ara h 2 sample. 
To expand our understanding of the importance of a diketone reacting group in 
performing allergoid synthesis reactions with Ara h 2, 2,3-Butandione, 2,3-Hexandione, 
3,4-Hexanedione, and 2,3-Heptanedione were evaluated. Currently there are no prior 
works identifying the ability of these reagents to modify the peanut allergen protein Ara h 
2. Each reagent displayed strong evidence of crosslinking, however 2,3-Hexandione was 
observed to be the most effective reagent to crosslink Ara h 2. Our successful attempts 
led us to the understanding that 2,3-Butandione, 2,3-Hexandione, 3,4-Hexanedione, 2,3-
Heptanedione and therefore the diketone group in phenylglyoxal could be essential in 
crosslinking Ara h 2 through glycol and glycosylation reactions. It should also be noted 
that O’Hehir48 claimed in their patent potential success in crosslinking Ara h 2 using 
Phenylglyoxal, 2,3-Butandione, and 2,3-Hexandione, however no scientific studies could 
be located to support this claim until now. 
It is also worth noting that aside from the 2nd derivative series evaluated there 
were 2 additional reagents evaluated that displayed evidence of crosslinking as well. The 
reagents were Aurintricarboxylic acid and ethyl 2,3-dihydroxybenzoate. Further research 
into the reason for modification with Aurintricarboxylic acid and ethyl 2,3-
dihydroxybenzoate is suggested since time prevented any further derivatives of these 
reagents from being evaluated. However, 2,3-dihydroxybenzoate contains a quinone 
group and successful reaction with Ara h 2 was observed in above 10.5 pH which is 
consistent with the reaction conditions and mechanism proposed by Chung46. 
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In-vitro immunoassays were also successfully performed and yielded results 
consistent with the degree of observable allergen structural change. A direct correlation 
was observed between the protein shift in mobility (observed by SDS-PAGE) and the 
concentration of the reaction compound used. According to Figure 10 all reagents tested 
appeared to successfully chemically modify Ara h 2 and physically disrupt epitope 
regions as identified by western blot. 
Several conditions were also evaluated to increase effectiveness during the initial 
compound screening experiments and proved invaluable in increasing the rate of 
identified hit compounds. The evaluated reaction conditions included variations in 
reaction buffer, reaction buffer pH, exposing the reaction mixture to agitation vs. non-
agitation, reaction temperature, concentration of reagent exposed to protein, and time 
exposed to protein we all evaluated to understand which conditions were ultimately most 
effective in forming an allergoid. To determine which reagent concentrations to use with 
the protein a large range of concentrations was evaluated to identify where the extremes 
were and to identify the potential working concentration. The apparent working reagent 
concentration was determined to be between 25mM - 50mM. A standard range of 
250mM - 1mM reagent concentration was frequently used to obtain the optimal working 
range for each reagent examined. Upon identifying which reagents react with Ara h 2, it 
is then necessary to make the fine-tune adjustments to optimize the allergoid where these 
adjustments can even as extensive as acquiring the chemical derivatives for the molecules 
being tested to determine the potential for stronger reactivity when compared to the 
original parent molecule structure.  
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Protein concentration was also important to remain as consistent as possible under 
the circumstances so to only evaluate one variable at a given time. The desired working 
protein concentration was around 1 – 2mg/mL, which was the seemingly effective 
working concentration identified by past researchers who determined that a 5mg/mL 
mixture of Ara h 2 and Ara h 6 was appropriate to modify Ara h 2 with phytic acid 49. 
Conclusions 
Moving forward we hope to increase our understanding of the allergoid chemical 
structure as well as identifying if any therapeutic benefits exist. Further characterization 
experiments are needed to better understand the allergoid structure, and to possibly make 
further modification enhancements that could benefit the overall product. In addition to 
characterization, higher order biological testing is also necessary to identify product 
stability and to determine what possible therapeutic benefits this product is capable of. It 
is also essential to provide further understanding for the allergoid theory in general, 




























Figure 11. Ara h 2 crosslinking reaction mechanism. (a) Abbreviated Ara h 2 dimer and 
trimer formation reaction using diketone reagents and phenylglyoxal derivative 
compounds (only phenylglyoxal parent structure displayed here). (b) Phenylglyoxal 
mediated Ara h 2 crosslinking reaction through accessible arginine residues producing a 
crosslinking event between protein 1 and 2 (P1 and P2). In this schematic, reactants are 
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